Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 26.92 -3.10% -0.86
ACAD closed down 3.1 percent on Friday, January 19, 2018, on 2.11 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
10 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ACAD trend table...

Date Alert Name Type % Chg
Jan 19 Stochastic Reached Oversold Weakness 0.00%
Jan 19 Wide Bands Range Expansion 0.00%
Jan 19 Oversold Stochastic Weakness 0.00%
Jan 18 Wide Bands Range Expansion -3.10%
Jan 18 Oversold Stochastic Weakness -3.10%
Jan 17 Narrow Range Bar Range Contraction -4.71%
Jan 17 NR7 Range Contraction -4.71%
Jan 17 Wide Bands Range Expansion -4.71%
Jan 16 180 Bearish Setup Bearish Swing Setup -4.37%
Jan 16 Wide Bands Range Expansion -4.37%

Older signals for ACAD ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 41.2
52 Week Low 25.06
Average Volume 1,671,514
200-Day Moving Average 31.2165
50-Day Moving Average 28.8708
20-Day Moving Average 28.889
10-Day Moving Average 28.03
Average True Range 1.0601
ADX 16.47
+DI 13.06
-DI 25.05
Chandelier Exit (Long, 3 ATRs ) 28.0597
Chandelier Exit (Short, 3 ATRs ) 30.0303
Upper Bollinger Band 31.1982
Lower Bollinger Band 26.5798
Percent B (%b) 0.07
BandWidth 15.986708
MACD Line -0.5623
MACD Signal Line -0.4209
MACD Histogram -0.1415
Fundamentals Value
Market Cap 3.3 Billion
Num Shares 122 Million
EPS -2.53
Price-to-Earnings (P/E) Ratio -10.64
Price-to-Sales 67.33
Price-to-Book 10.21
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.78
Resistance 3 (R3) 28.96 28.53 28.47
Resistance 2 (R2) 28.53 28.05 28.44 28.37
Resistance 1 (R1) 27.72 27.76 27.51 27.54 28.26
Pivot Point 27.29 27.29 27.18 27.20 27.29
Support 1 (S1) 26.48 26.81 26.27 26.30 25.58
Support 2 (S2) 26.05 26.52 25.96 25.47
Support 3 (S3) 25.24 26.05 25.37
Support 4 (S4) 25.06